Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on Inflammatory Bowel Disease (IBD) treatment, has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. The company will engage in a fireside chat and investor meetings on Tuesday, December 3, 2024, at 7:30 a.m. Eastern time.

The event will be accessible via webcast through the 'Events & Presentations' section of Spyre's investor relations website at ir.spyre.com, with a replay available after the conference.

News Market Reaction – SYRE

+0.07%

+0.07% Session move

In the trading session that priced this news, SYRE gained 0.07%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Nov. 25, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that will participate in a fireside chat and investor meetings at the 7th Annual Evercore ISI HealthCONx Conference. Details of the fireside are as follows:

• Tuesday, December 3, 2024, at 7:30 a.m. Eastern time 

To access this webcast, please visit the "Events & Presentations" page within the Investors section of the Spyre website at ir.spyre.com. An archive of the webcast will be available for replay following the end of the conference.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.

Follow Spyre Therapeutics on social media: @spyretx and LinkedIn

View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-the-7th-annual-evercore-isi-healthconx-conference-302315865.html

SOURCE Spyre Therapeutics, Inc.

FAQ

When is Spyre Therapeutics (SYRE) presenting at the Evercore ISI HealthCONx Conference 2024?

Spyre Therapeutics will present at the conference on Tuesday, December 3, 2024, at 7:30 a.m. Eastern time.

How can investors watch Spyre Therapeutics' (SYRE) presentation at the HealthCONx Conference?

Investors can access the webcast through the 'Events & Presentations' page in the Investors section of Spyre's website at ir.spyre.com.

What is the main therapeutic focus of Spyre Therapeutics (SYRE)?

Spyre Therapeutics focuses on developing treatments for Inflammatory Bowel Disease (IBD) using antibody engineering, rational therapeutic combinations, and precision medicine approaches.

Will there be a replay available of Spyre Therapeutics' (SYRE) HealthCONx Conference presentation?

Yes, an archive of the webcast will be available for replay following the end of the conference on Spyre's website.